Výsledky vyhledávání - "Gabriele Di Maggio"

The potential role of nintedanib in treating colorectal cancer

Autor: Paola Parente, Cinzia Chiarazzo, Gabriele Di Maggio, Antonio Rossi, Evaristo Maiello, Tiziana Latiano, Filomena Limosani

Publikováno v: Expert Opinion on Pharmacotherapy. 18:1153-1162

Angiogenesis leads to the growth, progression, and metastases of a variety of solid tumors, including metastatic colorectal cancer (mCRC), involving particularly the family of vascular endothelial growth factors (VEGF) and their receptors (VEGFR). Se

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa5651270bc4ff54ce81410fb5f561b7
https://doi.org/10.1080/14656566.2017.1346086

Zobrazit plný text záznamu

Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802)

Autor: Saverio Cinieri, Antonio Rinaldi, Massimo Di Maio, Roberto Bordonaro, Gabriele Di Maggio, Giuseppe Colucci, D. Rizzi, Michele Aieta, Salvatore Pisconti, Antonio Rossi, Tiziana Latiano, Francesco Giuliani, Antonio Febbraro, Stefano Cordio, Evaristo Maiello

Publikováno v: Clinical colorectal cancer. 19(2)

Introduction Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC). Bevacizumab plus FOLFOX-4 (oxaliplatin, folinic acid, and infusional 5-fl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7695daecefe5cc7deeff4a56a79439fc
https://pubmed.ncbi.nlm.nih.gov/32089455

Zobrazit plný text záznamu

Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX

Autor: Francesco Sponziello, Saverio Cinieri, Giuseppe Grimaldi, Alessandra Cassano, M. Biglietto, Pietro Micheli, Gianni Simone, C. Barone, Fabiana Tatangelo, Antonella Marino, Giacomo Cartenì, Guglielmo Nasti, D. Rizzi, Antonio Febbraro, Cinzia Chiarazzo, Mario Manusia, Vito Lorusso, Fortunato Ciardiello, A.R. Bordonaro, S. Romito, Sabrina Rossi, Teresa Troiani, F. De Vita, Eugenio Tommaselli, Giuseppe Colucci, Andrea Onetti Muda, Guido Giordano, Luigi Leo, G. Modoni, Annamaria Sebastio, Sandro Barni, Francesco Giuliani, Paolo Graziano, M. Rachiglio, Michele Aieta, Evaristo Maiello, Enrica Martinelli, Mirko Montrone, Silvana Leo, Tiziana Latiano, Stefano Cordio, Laura Longhitano, Vincenzo Rosario Iaffaioli, Vincenzo Montesarchio, Nicola Normanno, Anna Nappi, Matilde Lambiase, Gerardo Botti, Gabriele Di Maggio, Giuseppe Tonini, Nicoletta Chicchinelli, Oscar Nappi, Claudia Cardone, Michele Orditura, A. Rinaldi, Salvatore Pisconti, Tiziana Guarino

Background Cetuximab plus chemotherapy is a first-line treatment option in metastatic KRAS and NRAS wild-type colorectal cancer (CRC) patients. No data are currently available on continuing anti-epidermal growth factor receptor (EGFR) therapy beyond

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::343fea2703fb6409297f48937f6f6bde
http://hdl.handle.net/11591/354385

Zobrazit plný text záznamu

Bevacizumab (B) + bi-weekly capecitabine (C) and oxaliplatin (O) (XELOX2) or FOLFOX4 in first-line treatment of metastatic colorectal cancer (mCRC): Final results of a multicenter randomized phase II trial of the Gruppo Oncologico dell’Italia Meridionale (GOIM protocol 2802)

Autor: Salvatore Pisconti, D. Rizzi, Evaristo Maiello, Tiziana Latiano, Antonio Rinaldi, Massimo Di Maio, Antonio Febbraro, Roberto Bordonaro, Saverio Cinieri, Giuseppe Colucci, Gabriele Di Maggio, Francesco Giuliani, Stefano Cordio, Michele Aieta

Publikováno v: Journal of Clinical Oncology. 36:3542-3542

3542Background: B plus bi-weekly FOLFOX4 or three-weekly XELOX represents a standard 1-line therapy for mCRC pts. In our previous phase II study (Fedele P et al, ASCO 2009) we demonstrated a simila...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7685538b648779087df7c4803c81f89e
https://doi.org/10.1200/jco.2018.36.15_suppl.3542

Zobrazit plný text záznamu

Combined modality treatments in pancreatic cancer

Autor: Nicola Silvestris, Tiziana Latiano, L. Nanni, Giuseppe Colucci, Pierluigi Di Sebastiano, Saverio Cinieri, Gabriele Di Maggio, Lucia Lombardi, Michele Troiano, Evaristo Maiello

Publikováno v: Expert opinion on therapeutic targets. 16

Introduction: Of all the carcinomas, pancreatic carcinoma (PC) has the highest mortality rate, with a 1- and 5-year survival rate of 25% and less than 5% respectively. This is regardless of the stage at diagnosis. Areas covered: In this review releva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b14e43ccd7f91015ff09b258acfe9cc
https://pubmed.ncbi.nlm.nih.gov/22443336

Zobrazit plný text záznamu

Hypermethylation of the KEAP1 gene in colorectal cancer and association with disease progression

Autor: Vito Michele Fazio, Paola Parrella, Evaristo Maiello, Annamaria la Torre, Gabriele Di Maggio, Raffaela Barbano, Michelina Coco, Barbara Pasculli, Lucia Anna Muscarella, Tiziana Latiano

Publikováno v: Journal of Clinical Oncology. 31:e14655-e14655

e14655 Background: Aberrant methylation of the KEAP1 (Kelch-like ECH-associated protein 1) gene promoter is emerging as a main mechanism of dysregulation of the NrF2 (nuclear factor-erythroid 2-related factor 2 ) which plays a pivotal role in the cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d5ab5aca8142aac3fa7b1dcd86293e5
https://doi.org/10.1200/jco.2013.31.15_suppl.e14655

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání